亚博下载app-安卓版下载

Signed Agreement with Cell Culture Company (C3) for Manufacturing of Clinical Grade Antibody to Support Planned Clinical Studies

Chinese BioPharma Awards Minnesota Company Therapeutic Contract

Signed Agreement with Cell Culture Company (C3) for Manufacturing ofClinical Grade Antibody to Support Planned Clinical Studies EDMONTON, ALBERTA, November 2, 2016 – OncoQuest Inc.(“OncoQuest’), a biopharmaceuticalcompany focused on the development and commercialization of immunotherapeuticproducts for the treatment of cancer, today announces that itsJoint Venture Partner in China, OncoVent Co., Ltd. (“OncoVent”) has launchedits clinical development program for Anti-MUC1 MAb AR20.5 for the treatment ofpancreatic cancer. Based on the previous clinical experience and recentlyannounced positi…

China-based global pharmaceutical focusing on the development of combination immunotherapy for the China market